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#"	$: Preclinical evidence suggests that activation of cannabinoid receptor 1 
(CB1) has antitumor effects in colorectal cancer (CRC). GPR55 shares endogenous and 
synthetic ligands with CB1 and was found to promote CRC in this study by mechanisms that 
involve modulation of tumor?promoting factors. Additionally, differential regulation of DNA 
methylation and expression of CB1 and GPR55 was observed in human CRC patients, 
suggesting opposing roles of two cannabinoid?responsive receptors.  
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
The putative cannabinoid receptor GPR55 has been shown to play a tumor?promoting role in 
various cancers, and is involved in many physiological and pathological processes of the 
gastrointestinal (GI) tract. While the cannabinoid receptor 1 (CB1) has been reported to 
suppress intestinal tumor growth, the role of GPR55 in the development of GI cancers is 
unclear. We, therefore, aimed at elucidating the role of GPR55 in colorectal cancer (CRC), 
the third most common cancer worldwide.  
Using azoxymethane (AOM)? and dextran sulfate sodium (DSS)?driven CRC mouse models, 
we found that GPR55 plays a tumor?promoting role that involves alterations of leukocyte 
populations, i.e. myeloid?derived suppressor cells and T lymphocytes, within the tumor 
tissues. Concomitantly, expression levels of COX?2 and STAT3 were reduced in tumor tissue 
of GPR55 knockout mice, indicating reduced presence of tumor?promoting factors. By 
employing the experimental CRC models to CB1 knockout and CB1/GPR55 double knockout 
mice, we can further show that GPR55 plays an opposing role to CB1. We report that GPR55 
and CB1 mRNA expression are differentially regulated in the experimental models and in a 
cohort of 86 CRC patients. Epigenetic methylation of 45 and 5** was also 
differentially regulated in human CRC tissue compared to control samples.  
Collectively, our data suggest that GPR55 and CB1 play differential roles in colon 
carcinogenesis where the former seems to act as oncogene and the latter as tumor 
suppressor.  

$		
Despite benefits from early screening, colorectal cancer (CRC) remains a leading cause 
among cancer?related deaths emphasizing the need for new treatment options.1 Recent 
studies indicate that in addition to traditional chemotherapy, immunotherapy may become a 
valuable option of treatment against CRC.2 Knowledge on leukocytes, inflammatory 
mediators and their receptors within the tumor microenvironment is therefore crucial in order 
to explore and design new immunotherapies. Although CRC can be traced back to a familial 
basis such as adenomatous polyposis in some cases, the majority of incidences are sporadic 
cases and likely caused by environmental components and by inflammation of the colon 
(reviewed in 3). For instance, cyclooxygenase (COX)?2?derived mediators, transcription 
factors like STAT3 and NF?κB, and cytokines involved in intestinal inflammation, are now 
regarded as driving factors in colon carcinogenesis3, suggesting that molecules involved in 
gastrointestinal (GI) homeostasis are also critical in the development of GI cancer.  
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In this context, the endocannabinoid system is of great interest as it plays a prominent role in  
physiological and pathophysiological processes of the GI tract4. Cannabinoid (CB) receptors,  
in particular CB1, but also other cannabinoid?responsive G protein?coupled receptors  
(GPCRs), such as the G protein?coupled receptor 55 (GPR55), are expressed in the GI tract  
and they are fundamentally involved e.g. in the regulation of motility and inflammation4,5. In  
experimental models of colitis, CB1 and CB2 receptors exert anti?inflammatory properties
6,7  
while GPR55 has been linked to pro?inflammatory processes8. Genetic deletion of the CB1  
receptor provokes a strong increase in intestinal tumors in  -6 mice9. The role of GPR55  
in GI carcinogenesis, however, has not been fully elucidated so far.  
Activity of GPR55 has been shown to be modulated by the endocannabinoids anandamide  
and virodhamine10. In turn, CB1 may regulate the signaling properties of GPR55
11. Thus,  
despite sharing little homology with the classical CB receptors12, GPR55 can be considered  
part of an expanded endocannabinoid system. Contrary to CB receptors, GPR55 initiates  
excitatory rather than inhibitory effects by signaling through Gα12/13 and Gq proteins
13, which  
are known to promote carcinogenesis14. Its structure is closely related to other cancer? 
relevant GPCRs, such as GPR35, GPR92 and GPR2315. GPR55 expression has been  
demonstrated in several types of tumor cell lines, such as breast, prostate, ovarian and colon  
cancer cells16–18. 	
, the receptor promotes carcinogenesis in a mouse model of skin  
cancer19. With the exception of cholangiocarcinoma20, a majority of studies propose a pro? 
oncogenic role for GPR5516–19. Beside cancer cells, GPR55 is expressed in various types of  
leukocytes, such as macrophages8, neutrophils21, and lymphocytes22. Recently, we showed  
that the receptor drives intestinal inflammation via mechanisms involving leukocyte  
infiltration8. We have further elucidated an involvement of GPR55 in migration and adhesion  
of colon cancer cells and in liver metastasis18. These effects were sensitive to the GPR55  
antagonist CID1602004611,18. We have also found that levels of the endogenous ligand, L?α? 
lysophosphatidylinositol (LPI)23 were higher in blood samples of colon cancer patients than in  
control individuals18. Other groups demonstrated an important role of the LPI?GPR55 axis in  
breast cancer metastasis24,25. Because of its potentially pro?carcinogenic behavior and its  
actions within the endocannabinoid system contrary to those of CB1
8, we systemically  
explored the role of GPR55 in GPR55 knockout (GPR55?/?) and wild?type mice using a mouse  
model of azoxymethane (AOM)? and dextran sulfate sodium (DSS)?induced CRC that  
displays robust infiltration of inflammatory cells, a feature not only seen in colorectal tumors  
connected to inflammatory bowel diseases (IBD) but also in CRC not associated with IBD3.  
We also created CB1/GPR55 double knockout (CB1
?/?GPR55?/?) mice and performed  
experiments in these mice.   
Our findings reveal that tumor burden in the colon of GPR55?/? mice was lower than in wild? 
types and this was in contrast to what we observed in CB1 knockouts (CB1
?/?) which displayed  
This article is protected by copyright. All rights reserved.
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higher tumor burden in the colon. In the CB1
?/?GPR55?/? mice, these effects were 
compensated as their tumor burden did not differ from that of their wild?type littermates. 
Unexpectedly, pharmacological manipulation of GPR55 in colon cancer cell lines failed to 
show effects on proliferation. However, in comparison with wild?type littermates, tumors of 
GPR55?/? mice revealed down?regulation of COX?2 and STAT3, increased influx of cytotoxic 
CD8+ T?cells and decreased infiltration of myeloid?derived suppressor cells (MDSC; a 
heterogeneous population of immature myeloid progenitor cells that suppresses immune 
responses), indicating that a change in the tumor microenvironment of GPR55?/? mice may be 
involved in the inhibitory effects on carcinogenesis.  
 
%	%
	
For analyzing the influence of GPR55 expression on CRC patient clinical outcome, we made 
use of a publicly available data set generated on an Affymetrix U133 Plus 2.0 chip platform 
(GSE39582). This data set contains whole transcriptome data of 566 CRC patients as 
previously described26. For analysis of these data used of a visualization software [R2: 
microarray analysis and visualization platform (http://r2.amc.nl)]26. Nine patients lacked 
survival data and were omitted automatically by the software, resulting in overall 557 
available samples. Differences in 10?years relapse?free survival between groups of high and 
low GPR55 expression were tested by using a cut?off point determined automatically by the 
software. Survival was illustrated by a Kaplan?Meier curve, and differences in survival 
between dichotomized groups were assessed with the log?rank test.  
DNA methylation and transcriptomics data were obtained from CRC patients as part of the 
&
3, project (www.oncotrack.eu). Written informed consent was obtained from all 
patients. Ethical approval was granted by the ethics committee of the Medical University of 
Graz (23?015 ex 10/11).  
The methylation status of 45 and 5** in CRC samples and adjacent healthy mucosa 
was assessed using the Illumina 450K Infinium Human Methylation BeadChip27. mRNA 
expression of CB1 and GPR55 was assessed according to standardized procedures. 
Normalization was done using the RPKM method27,28.  
%
GPR55?/? mice were acquired from the Mutant Mouse Resource & Research Center and bred 
in house19. CB1
?/? breeding pairs were kindly provided by A. Zimmer. CB1/GPR55 double 
knockout (CB1
?/?GPR55?/?) mice were created by crossing the two strains. Experimental 
procedures were approved by the Austrian Federal Ministry of Science, Research and 
Economy (protocol number: BMWF?66.010/0112?WF/II/3b/2014) and performed in strict 
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accordance with international guidelines. All efforts were made to minimize suffering. 
Experiments were started when mice were 5?7 weeks old and weighed about 20 g.  
%

Colitis?associated CRC was induced in CB1
?/?, GPR55?/?, CB1
?/?GPR55?/? mice, and respective 
wild?type littermates on a C57Bl/6 background as described29. AOM was obtained from 
Sigma (Vienna, Austria), and DSS from MP Biomedicals (Illkirch, France). Mice were 
sacrificed on day 80 for tissue collection and on day 108 for analysis of leukocytes recruited 
into the tumors. Colon tissue was also collected from age?matched healthy mice. For the 
pharmacological approach, CD1 mice ? a strain that is more susceptible to this model ? were 
obtained from Charles River (Germany). Either 5 mg/kg CID16020046 (GPR55 antagonist; 
ChemDiv, San Diego, CA, USA) or dimethyl sulfoxide (vehicle control; VWR, Vienna, Austria) 
diluted in PBS (Pan?Biotech, Aidenbach, Germany) were applied s.c. on days 22?28 and 38?
46. Tumors were evaluated on day 100. In graphs that show data from the mouse model 
experiments, each data point corresponds to tumors obtained from one individual mouse. 
%			
Spontaneous tumor progression was induced in CB1
?/? and GPR55?/? mice, and C57Bl/6 wild?
type littermates as described29. Tumors were evaluated 6 months (CB1) or 8 months 
(GPR55) after the last AOM injection.  

Colon cancer cell lines HCT116, SW480, SW620, HT29 and DLD?1 were obtained from 
Interlab Cell Line Collection (Genova, Italy), CaCo?2 from ATCC (Manassas, VA, USA). 
HCT116 and HT29 were maintained in McCoy’s 5A, SW480, SW620, DLD?1, and CaCo?2 in 
DMEM, both supplemented with 10% FBS (all Life Technologies, Vienna, Austria), 2 mM L?
glutamine and 1% penicillin/streptomycin (both PAA Laboratories, Pasching, Austria), at 
37°C, 5% CO2 in a humidified atmosphere. Cells stably overexpressing GPR55 were 
generated by transfecting SW480 with pcDNA3.1 coding for GPR55 with an N?terminal 
hemagglutinin tag (3xHA?GPR55), as described30. Transfected cells were selected with 4 
mg/ml G418 (Life Technologies) and grown to confluence. Cells were then sorted on a 
FACSAria (BD Biosciences, Franklin Lakes, USA) after staining with anti?HA (Covance 
#MMS?101P) and goat anti?mouse Alexa 488 (Thermo Scientific #A?21121) antibodies. 
Sorted cells were maintained in DMEM supplemented with 0.5 mg/ml G418.  
Cell viability was assessed after treatment with LPI (GPR55 agonist; Sigma) or CID16020046 
as previously described18.  
Cell lines were authenticated by DNA short?tandem repeat analysis by the Cell Culture 
Facility of the Center for Medical Research at the Medical University of Graz (Austria). 
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	'"	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
RNA was extracted from tissue using TRIzol (Life Technologies) and from cultured cells with 
RNeasy Kit (Qiagen, Hilden, Germany). Samples were treated with DNA?free DNA Removal 
Kit (Life Technologies) and 2Wg of total RNA were then reverse transcribed to cDNA using 
High?Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, USA). 
Quantification of gene expression was carried out by real?time PCR using SsoAdvanced 
Universal SYBR Green Supermix (Bio?Rad, Vienna, Austria). Primers were acquired from 
Bio?Rad (listed in Supplementary Table 1) and relative gene expression was assessed 
according to the ∆∆Cq?method.  
	&	'+		'	,		
For protein extraction and Western blotting, protocols from Cell Signaling Technology (CST) 
were followed. Antibodies used were: COX?2 (ab15191, 1:1000), NF?κB (CST 4764, 1:1000), 
STAT3 (CST 4904, 1:1000), p(Tyr705)?STAT3 (CST 9145, 1:1000), PCNA (Dako M0879, 
1:1000), Bax (CST 2772, 1:1000), Bcl?xL (CST 2764, 1:1000), β?actin (Sigma A5316, 
1:7500), and GAPDH (CST 5174, 1:1000); goat?anti?mouse (#115?036?062) or goat?anti?
rabbit antibody (#111?036?045, both Jackson ImmunoResearch, 1:5000). Detection was 
performed on a ChemiDoc Touch Imaging System using Clarity Western ECL Blotting 
Substrate (both Bio?Rad). Immunoblot images were analyzed with Image Lab 5.2 software 
(Bio?Rad). Band intensities of proteins of interest were normalized against band intensities of 
loading controls and ratios are presented in arbitrary units. GAPDH was found to be stably 
expressed over different tissues, but β?actin gave better stability for comparison between 
tumors of GPR55?/? and wild?type mice. Cytokine expression was measured using the 
ProcartaPlex Multiplex Immunoassay (affymetrix eBioscience, Vienna, Austria).  
$			-	
Colon sections were stained as described previously8. The following antibodies were used: 
COX?2 (ab15191, 1:2000), STAT3 (CST 4904, 1:500), and CD3 (ab5690, 1:1000). Antibody 
binding was visualized with ImmPACT NovaRed (Vector Laboratories) and sections were 
counterstained with hematoxylin. Images were taken with a high resolution digital camera 
(Olympus DP 50) and analyzed by Cell^A imaging software (Olympus, Vienna, Austria). Only 
contrast and brightness of images were adjusted.  
For cellular detection of GPR55 mRNA in colonic sections, RNAscope® 2.5 Chromogenic 
Assay with RNAscope® mouse GPR55 probe (#318231; ACD Advanced Cell Diagnostics, 
Hayward, CA, USA) was used according to the manufacturer’s instructions.  
%
Prostanoids from mouse tissue were analyzed by liquid chromatography?mass spectrometry 
(LC?MS/MS) as previously described31.  
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Tumors were excised from the colon, cut into small pieces with a scalpel and washed with 
HBSS containing 20 mM HEPES and penicillin/streptomycin (P/S) 4 x 10 min at room 
temperature. Intraepithelial immunocytes were extracted by incubation with HBSS containing 
10 mM EDTA, 2.5% FBS, and P/S for 4 x 20 min at 37°C on a rotating device. The tissue 
was washed with RPMI and digested with RPMI supplemented with 5% FBS, 10mM HEPES, 
P/S, and 200 U/ml collagenase type II for 1 hour at 37°C (all Life Technologies). Isolated 
cells were passed through a 40Wm cell strainer, washed with PBS once, and leukocytes were 
stained for flow cytometry. Cells were stained with the following antibodies (all BD, Vienna, 
Austria) for 1 hour at 4°C: CD45?APC (1:200, clone: 30?F11), CD3e?BV510 (1:100, clone 
145?2C11), CD4?PE?Cy7 (1:500, clone RM4?5), CD8a?APC?H7 (1:100, clone 53?6.7), 
CD11b?FITC (1:200, clone M1/70), Ly6G?BV421 (1:500, clone 1A8), Ly6C?PE?Cy7 (1:200, 
clone AL?21), CD16/32 (1:100, clone 2.4G2). Samples were analyzed on a BD FACS Canto 
II flow cytometer. Analysis was done with FlowJo 4.0 software.  
(		)		
Demethylation of colon cancer cell lines was induced as previously described32. Briefly, cells 
were treated with 5?aza?2’?deoxycytidine (Sigma) for 3 days, DNA was extracted using 
Gentra Puregene Cell Kit and bisulfite conversion was performed with the EpiTect Bisulfite 
Kit (both Qiagen). Primers (listed in Supplementary Table 2) spanning three regions of 
interest determined from methylation data obtained from CRC patients, i.e. chr2:231774770 
in the gene body (“body”), chr2:231789465 in the 5’?untranslated region (“5’?UTR”), and 
chr2:231790813, upstream of the transcription start site (“TSS”) were designed using Methyl 
Primer Express (Life Technologies) with hg19 as a reference. The regions of interest were 
amplified using the HotStar Taq® Master Mix Kit (Qiagen) and sequenced using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies) according to the manufacturer’s 
protocol. The sequencing reactions were purified using Sephadex G50 Superfine (Sigma) 
and sequenced on an ABI 3130xl Genetic Analyzer. Sequences were analyzed using the 
SeqScape software (Life Technologies) and CpG methylation was calculated as a function of 
the area under the curve of the C and the T traces.  
	
Statistical analysis of 	
 and 	
 experiments was performed with GraphPad Prism 
4.0 (GraphPad Software, La Jolla, CA, USA). Treatment groups were compared using 
unpaired two?tailed student’s t?test unless stated otherwise. Welch’s correction was applied if 
variances were unequal.  
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.	
In a mouse model of AOM+DSS?induced colitis?associated CRC, GPR55?/? mice showed 
~50% less tumors than their wild?type littermates. Accordingly, the average total tumor areas 
were also reduced by ~50% in GPR55?/? mice (Fig. 1A). Histological evaluation of the tumors 
revealed that in both GPR55?/? and wild?type mice, criteria of tubular?villous adenomas with 
low and high grade intraepithelial neoplasia occurred (Fig. 1B). In GPR55?/? mice, the nuclear?
cytoplasmic ratio was changed towards a higher nucleus size, however, nuclei were located 
predominantly at the cell base. Wild?type mice showed enlarged nuclear sizes accompanied 
by hyperchromasia and irregularity of tumor cell shape and nuclear shape. Nuclei were 
largely apically located. The cytoplasm appeared strongly basophilic. Nuclear clearing was 
observed particularly in wild?type mice and, albeit to a much lesser degree, also in GPR55?/? 
mice. No sign of invasion was detected in either group. In general, GPR55?/? mice exhibited a 
more low grade form of neoplasia compared to the low to high grade form of tumors in the 
wild?type mice.  
Pharmacological inhibition of GPR55 with the antagonist CID16020046 also led to a 
decreased tumor burden in colitis?associated CRC in wild?type mice. Treatment with 
CID16020046 (5 mg/kg) caused a reduction in tumor numbers and areas compared to 
vehicle control treatment (Fig 1C). Since chronic inflammation is the driving force of the 
colitis?associated CRC model and as GPR55 has recently been shown to play a pro?
inflammatory role in colitis8, we subjected mice also to an inflammation?independent model of 
repeated AOM administration. In this model of spontaneous tumor progression, GPR55?/? 
mice again had less tumors and smaller total tumor areas than wild?type littermates (Fig. 1D).  
For human cross validation, we analyzed a publicly available clinical CRC expression data 
set (n=557) and found a significant (	= .016) association between high GPR55 expression 
and shortened relapse?free survival (Fig. 1E). These findings suggest that GPR55 plays a 
tumor?promoting role in colon carcinogenesis.  
	"		
To investigate the mechanism through which GPR55 exerts its pro?tumorigenic function we 
first performed proliferation assays with CRC cell lines. Although all cell lines examined 
expressed GPR55 (Supp Fig. 1A), we did not find any effects of the agonist LPI or the 
antagonist CID16020046 on cell proliferation (Supp Fig. 1 B,C), cell cycle distribution or 
apoptosis (data not shown). Since our in situ hybridization data indicated that GPR55 was 
not only present on epithelial cells but also on cells of the lamina propria and of lymph 
follicles from healthy murine colonic mucosa as well as in various cells within the tumor 
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tissue of AOM+DSS treated mice (Fig. 1F and Supp Fig. 2), we focused on the analysis of 
collected tissues.  
Prostaglandin H2 synthesizing enzyme cyclooxygenase 2 (COX?2) as well as transcription 
factors NF?κB and STAT3 have been described to constitute some of the most important 
pathways in inflammation?induced cancer3,33,34. Indeed, we observed that COX?2 and STAT3 
expression were increased in non?tumor and even more in tumor tissue as compared to 
healthy control colon (Supp Fig. 3). Comparison of tumor tissue collected from GPR55?/? mice 
and wild?type littermates revealed that COX?2 and STAT3 expression were reduced in 
tumors of GPR55?/? mice (Fig. 2 A?C). Notably, reduction of COX?2 and STAT3 expression 
was not limited to immunocytes but rather also occurred in tumor cells of GPR55?/? mice (Fig. 
2C). Reduced levels of NF?κB and phosphorylated STAT3 were also observed although 
statistical significance was slightly missed (p=0.067 and p=0.08, respectively, Fig. 2 A,B and 
Supp Fig. 4). Down?stream effector molecules of COX?2, i.e. thromboxane A2 (as 
determined by measurement of the primary metabolite thromboxane B2 (TXB2)) and 
prostaglandin F2α (PGF2α), were also found to be expressed at a lower level in tumor tissue 
of GPR55?/? mice (Fig. 2D). Cytokine analysis further showed that interleukins 5, ?10, and ?12 
(IL?5, IL?10, IL?12) were elevated in tumors of GPR55?/? mice, whereas the expression of 
myeloid cells?recruiting chemokine monocyte chemoattractant protein?1 (MCP?1/CCL2) was 
diminished (Fig. 2E). Analysis of the cell proliferation marker proliferating?cell?nuclear?antigen 
(PCNA) showed a slight decrease in tumors of GPR55?/? mice, whereas apoptosis markers 
Bax and Bcl?xL were not significantly altered (Fig. 2F).  
Together, these observations indicate that GPR55 might be involved in the 
immunomodulation of the tumor microenvironment. We thus analyzed the leukocyte 
populations recruited into tumors of wild?type and GPR55?/? mice. Since it has been recently 
reported that deletion of CCL2 reduced carcinogenesis in colitis?associated CRC via reduced 
infiltration of MDSCs35, we examined this cell population in our model. Indeed, we found that 
tumors of GPR55?/? mice showed reduced numbers of CD11b+Ly6C+Ly6G? cells (Fig. 3 A,B), 
which have been described as monocytic MDSCs35,36. MDSCs are reported to contribute to 
colonic tumor growth in colitis?associated CRC via T cell inhibition36. Accordingly, tumors of 
GPR55?/? mice displayed strongly enriched numbers of CD3+ leukocytes (Fig. 3C). Further 
analysis of the CD3+ cell population revealed an increase in both CD4+ and CD8+ T cells 
(Fig. 3 D,E). To double check for the presence of T cells, colonic sections were also stained 
immunohistochemically for CD3 (Supp Fig. 5). GPR55 has been reported to be expressed by 
various leukocytes22,37,38 and GPR55 antagonism has been shown to modulate the migratory 
behavior of cells8,18,38. Therefore, we examined whether the above mentioned alterations in 
the tumor microenvironment could be caused by “per se” effects of the genetic deletion of 
GPR55. As shown in Supp Fig. 6A, however, the amount of leukocytes recruited into the 
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tumors did not differ between GPR55?/? and wild?type mice. Expression levels of COX?2 and 
STAT3 in healthy control colon were not statistically different, either (Supp Fig. 6 B,C).  
Taken together, our data thus indicate that GPR55 probably alters the composition of the 
leukocyte population that is recruited during colorectal carcinogenesis resulting in the 
formation of a tumor?promoting microenvironment that leads to increased expression of 
tumor?promoting molecules (Fig. 4).  
/		
Since CB1 has been shown to play a tumor?suppressing role in a genetic mouse model of 
intestinal cancer9 in which polyps developed mainly in the small intestine ( -6 mice), we 
were interested to see whether CB1 would also be protective in our models of CRC. Indeed, 
we found that CB1
?/? mice developed significantly more tumors and, accordingly, had larger 
tumor areas than wild?type littermates in both models of colon cancer, i.e. in the model of 
spontaneous tumor progression and in the colitis?associated CRC model (Fig. 5 A,B). These 
data suggest that CB1 plays a contrary role to GPR55 in CRC. To further support this notion, 
we applied the colitis?associated CRC model to CB1/GPR55 double knockout mice and wild?
type littermates. As shown in Fig. 5C, there was no difference in tumor burden, i.e. neither in 
tumor numbers nor in tumor areas, between CB1?/?GPR55?/? mice and wild?type littermates, 
suggesting that the tumor?promoting role of GPR55 is indeed opposed by the tumor?
suppressive role of CB1.  
/							 
		
Wang 	 recently reported that the tumor?suppressive role of CB1 could be diminished in 
CRC because of epigenetic hypermethylation of the 45 promoter that results in reduced 
transcription9. Following up on this finding, we examined expression levels of CB1 and 
GPR55 mRNA in tissue collected from the colitis?associated CRC mouse model and from a 
cohort of 86 CRC patients. In the mouse model of colitis?associated CRC we observed that 
in tumor tissue, CB1 expression was indeed strongly reduced as compared to healthy control 
colon. The colonic non?tumor tissue, i.e. tissue affected by multiple exposures to DSS but 
devoid of neoplastic lesions, showed an increase in CB1 mRNA levels as compared to 
healthy colon (Fig. 6A). On the contrary, GPR55 mRNA levels were decreased in non?tumor 
tissue and increased in tumor tissue compared to colon tissue of healthy control mice (Fig. 
6B). In CRC patients, CB1 mRNA levels were drastically reduced in tumors of TNM stage I as 
compared to control tissue. With increased severity of disease, however, CB1 mRNA levels 
increased again (Fig. 6C). GPR55 mRNA levels, on the other hand, decreased with 
increasing stage (Fig. 6D). Taken together, our data indicate a differential regulation for the 
transcription of CB1 and GPR55 in murine and human CRC.  
Page 10 of 29
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
11 
 
0						
To further elucidate the aforementioned findings, we analyzed the methylation status of 
45 and 5** in our cohort of CRC patients. In line with the observations of Wang 	9, 
we found that 45 has a CpG island?associated promoter (Fig. 6E) that is characterized by 
low DNA methylation in healthy colonic mucosa controls (fraction of methylated cells 
[β]<0.11) with six probes significantly hypermethylated in CRC samples (∆β>0.04, 	< .01). 
These CpGs are located at ?755 to +268 with regard to the transcription start site (hg19 
coordinates 88875844 to 88875398). Additionally, we observed differences within 5’?UTR 
and gene body probes in open sea regions: in controls these regions of 45 are 
characterized by much higher methylation (β>0.54); in CRC, however, ten probes in this 
region are substantially hypomethylated compared with control (∆β=0.04?0.32, 	< .001). 
This phenotype is consistent with the idea that 45 is actively transcribed in both CRC and 
healthy controls, but that transcription is being nuanced toward down?regulation in CRC 
samples. In contrast, 5** does not have CpG islands and exhibits a rather global 
decrease in methylation (Fig. 6F) with four probes being significantly less methylated in CRC 
samples (∆β=0.03?0.07, 	< .01).  
0							
DNA demethylating agents, e.g. 5?aza?2’?deoxycytidine (5?aza?dC, “decitabine”) have been 
approved by the US Food and Drug Administration for the treatment of myelodysplastic 
syndrome and are currently being investigated for the treatment of solid tumors, including 
gastrointestinal cancer39. To examine the effect of epigenetic demethylation on the 
expression of GPR55, we treated six colon cancer cell lines with 5?aza?dC and analyzed the 
methylation status of 5** by bisulfite sequencing before and after treatment. 5** was 
heavily methylated in all CRC cell lines (Supp Fig. 7). SW480 cells, however, showed a 
slightly lower degree of methylation at CpGs in the gene body and 5’?UTR. Intriguingly, this 
cell line also expressed ~55?fold more GPR55 mRNA (see Supp Fig. 1A). Treatment with 5?
aza?dC caused a reduction of methylation and a concomitant increase of mRNA expression 
in 4 of 6 cell lines, i.e. DLD?1, HCT116, SW620, and HT29 cells. The methylation status of 
SW480 and Caco?2 cells was not altered upon treatment and, accordingly, GPR55 mRNA 
expression levels were unchanged (Fig. 6G).  
These findings prompted us to investigate whether overexpression of GPR55 in colon cancer 
cells could lead to a proliferative effect. Thus, we stably overexpressed the receptor in 
SW480 cells. Cell viability of native and GPR55?overexpressing SW480 (SW480?GPR55) 
cells was assessed after 24, 48, and 72 hours and revealed a significant growth advantage 
of SW480?GPR55 cells (Fig. 6H). These findings corroborate our hypothesis that GPR55 has 
a pro?tumorigenic role in CRC.  
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(	 
A tumor?promoting function has been established for GPR55 and its endogenous ligand LPI  
in a variety of cancers, including breast25, prostate and ovarian cancer17, squamous cell  
carcinoma19, and glioblastoma16. Recently, we have reported GPR55?mediated effects in  
adhesion and migration of colon cancer cells, as well as in experimental liver metastasis18.  
The role of GPR55 in colorectal carcinogenesis, however, has not been elucidated yet.   
Using the AOM+DSS?driven colitis?associated CRC model, we show that genetic deletion of  
GPR55 leads to reduced tumor burden in mice. Pharmacological inhibition of GPR55 with  
CID16020046 gave results that were similar to the genetic approach.   
In the current study, we focused on investigating the effects of genetic ablation of GPR55 in  
colorectal carcinogenesis. As summarized in Figure 4, we found that tumors of GPR55?/? mice  
exhibited modifications in the tumor microenvironment that were characterized by altered  
leukocyte populations in the tumors and a concomitantly reduced expression of tumor? 
promoting factors. For instance, reduced expression of the myeloid cell?recruiting chemokine  
CCL2 was observed. Deletion of CCL2 has been reported to reduce the recruitment of  
myeloid?derived suppressor cells (MDSCs) in colitis?associated CRC35. In line with this  
finding, we observed reduced numbers of monocytic MDSCs in GPR55?/? tumors. MDSCs  
suppress immune responses mediated by CD4+ and CD8+ T cells by inhibiting T cell  
proliferation, migration and function40. We observed increased numbers of both CD4+ and  
CD8+ T cells in tumors of GPR55?/? mice which could be a consequence of reduced amounts  
of MDSCs in the microenvironment. Importantly, CD3+ lymphocytes have been shown to be  
beneficial in CRC patients since increased numbers of CD3+ cells were associated with an  
increased disease?free survival41. Furthermore, we found that COX?2, a promising target in  
the prevention of CRC34, and COX?2?derived mediators PGF2α and TXB2, which have both  
been attributed tumor?promoting functions42,43, were expressed at lower levels in tumors of  
GPR55?/? mice. STAT3 signaling, which has been established to drive colon carcinogenesis  
33,44, was also reduced in tumors of GPR55?/? mice, which could partly be due to diminished  
CCL2?MDSC signaling35. Cytokine analysis further revealed increased levels of IL?5, IL?10,  
and IL?12 in tumors of GPR55?/? mice, which might be caused by increased numbers of T  
cells present in these tumors. While the role of IL?5 in CRC has not been fully clarified yet,  
clinical trials using recombinant human IL?10 (ClinicalTrials.gov identifier: NCT02009449)  
and IL?12 (NCT01417546) in solid tumors including CRC are currently ongoing. Taken  
together, our data suggest that abrogation of GPR55 indirectly reduces the expression of  
COX?2, STAT3, and PCNA in tumor cells resulting in reduced tumor growth, i.e. smaller  
tumor burden and lower grade neoplasia in GPR55?/? mice. This could explain why GPR55?/?  
mice had less tumors in our model. Other factors, however, might also play a role and remain  
to be investigated.   
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Since it has been postulated that the LPI?GPR55 axis enhances cancer cell proliferation45,  
we performed cell viability assays on two CRC cell lines, one with high GPR55 mRNA  
expression (SW480 cells) and one with low GPR55 mRNA expression (HCT116 cells).  
Interestingly, however, we did not detect any effect of the agonist LPI or the antagonist  
CID16020046 on the viability of either cell line. A possible explanation hereof could lie in the  
purported cross?regulation of CB1 and GPR55 meaning that GPR55 signaling was inhibited  
when CB1 and GPR55 were co?expressed in HEK293 cells
11. HCT116 and SW480 cells  
express both CB1
9 and GPR55 and, indeed, we observed that SW480 cells that stably  
overexpressed GPR55 had a growth advantage compared to native SW480 cells. Whether  
CB1 actually inhibits GPR55 signaling in CRC cells remains to be established.   
Although GPR55 is not considered a classical cannabinoid receptor but owing to its  
responsiveness to certain (endo?)cannabinoids, it can be regarded as part of an extended  
endocannabinoid system13. Since the endocannabinoid system is crucially involved in GI  
homeostasis and disorders4, we aimed at further investigating the role and regulation of CB1  
in CRC. Here, we report that genetic deletion of CB1 led to an increased tumor burden in  
both our experimental models, i.e. in colitis?associated and spontaneous colon cancer,  
corroborating the findings of Wang 	9 who observed a detrimental effect of CB1 deletion in  
a genetic model of colon cancer ( -6 mice). When CB1/GPR55 double knockout mice  
were subjected to the colitis?associated CRC model, no differences in tumor burden were  
found as compared to wild?type littermates. These are the first 	
 data that show that  
GPR55 and CB1 regulate colorectal carcinogenesis in an opposing manner.   
Receptor expression analysis of murine tissue further revealed a differential regulation of CB1  
and GPR55. While CB1 appeared up?regulated in inflamed non?tumor tissue and down? 
regulated in tumor lesions, GPR55 was found to be down?regulated in non?tumor tissue and  
up?regulated in tumors when compared to healthy control colon. These findings corroborate  
the hypothesis that colonic tumor growth is facilitated by the absence of tumor?suppressing  
CB1 and the presence of tumor?promoting GPR55.   
Since down?regulation of CB1 expression in tumors has been shown to be a result of  
epigenetic hypermethylation of CpGs in the promoter region of 45 in CRC patients9, we  
assessed the methylation status of 5**	and 45	in a cohort of 86 CRC patients. In  
accordance with previous findings9, DNA methylation analysis revealed a strong increase of  
promoter cytosine methylation in the CpG islands of 45	in CRC samples compared to  
control tissue. Contrarily, a decrease in methylation of 5** was found in tumor samples.  
Alterations in DNA methylation are ubiquitous in human cancers, with promoter CpG island  
hypermethylation occurring in the context of a global decrease in methylation46. Increased  
promoter cytosine methylation has been established to silence gene expression. 45  
promoter hypermethylation, therefore, is very likely to contribute to colon carcinogenesis  
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through silencing of tumor?suppressing CB1. GPR55 on the other hand does not have CpG 
islands in the promoter region and is, perhaps, subject to the genome?wide hypomethylation 
frequently observed in cancer47.  
In accordance with the above mentioned promoter hypermethylation, mRNA expression 
analysis revealed a strong down?regulation of CB1 in CRC samples compared to control 
tissue. Interestingly, CB1 expression levels were found increased with disease severity. 
GPR55 expression, in contrast, decreased with CRC stage in this cohort. These findings 
differ from previous reports stating that GPR55 mRNA expression is increased in several 
human tumors, e.g. pancreatic neoplasias and glioblastomas16. GPR55 expression levels, 
however, have also been shown to correlate with aggressiveness16 and, indeed as shown in 
Fig. 1E, high GPR55 expression was associated with a significantly reduced disease?free 
survival in CRC, confirming the tumor?promoting role of GPR55 in CRC.  
In conclusion, our data suggest that GPR55 plays an opposing role to CB1 in colon 
carcinogenesis with GPR55 acting as tumor?promoter and CB1 as tumor?suppressor. 
Pharmacological activation or blockade of GPR55 in cancer cell lines had no effect on 
proliferation. Rather, GPR55 may be responsible for alterations in the leukocyte composition 
of the tumor microenvironment to promote tumor growth. However, as GPR55?
overexpressing SW480 cells showed a growth advantage compared to native SW480 cells, 
direct effects of GPR55 on tumor cells in situ are conceivable. Our observations are of 
particular importance when targeting of the endocannabinoid system for future therapy of 
colorectal cancer is considered.  
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1	
1	. (!) In a model of colitis?associated CRC, 
GPR55?/? mice (n=36) had less tumors and smaller total tumor areas than their wild?type 
littermates (WT, n=44). (/) H&E staining from sections of tumors in the colon induced by 
AOM+DSS in GPR55?/? (left panel) and wild?type mice (right panel). Images are 
representative of 4 mice of each cohort. Inserts in the right upper corner of the images show 
adenomas in GPR55?/? and wild?type mice in lower magnification (size bars: 500 Wm). () 
Pharmacological inhibition of GPR55 with CID16020046 (5 mg/kg) reduced tumor numbers 
and areas compared to vehicle treatment (n=9 for both groups). (() Tumor numbers and 
areas were reduced in GPR55?/? mice (n=27) compared to wild?type mice (n=18) in a model 
of spontaneous tumor progression. (0) In CRC patients, high GPR55 mRNA expression in 
tumor tissue was significantly associated with reduced relapse?free survival (=.016, log?rank 
test). (1) Cellular detection of GPR55 mRNA with RNAscope ® 2.5 Chromogenic Assay 
using 3,3'?diaminobenzidine (DAB) as a chromogene (brown color). Sections were 
counterstained with hematoxylin (blue). Sections of colonic mucosa of healthy wild?type (WT) 
mice showed GPR55 expression (left panel), while the staining was absent in knockout 
(GPR55?/?) controls (middle panel). Tumors of wild?type mice expressed GPR55 mRNA in 
various cells (right panel).  
7 point at DAB precipitates at the sites of GPR55 mRNA 
expression in cells.  
7	denote heterochromatin (blue) in cell nuclei. Symbols depict 
data from individual mice, and bars show the mean. ** 	< .01, *** 	< .001 
12*
3
			"		4 (!) 
Western blotting revealed reduced expression levels of STAT3, COX?2, and NF?κB in tumors 
of GPR55?/? mice compared to wild?type (WT) mice. Images were obtained by stripping and 
re?probing of the membrane and are representative of 3 independent blots. (/) Statistical 
analysis of data obtained by Western blotting. () Sections of colonic tumors of GPR55?/? and 
wild?type mice were stained (brown color) for COX?2 and STAT3 expression showing clear 
reductions in the GPR55?/? mice. Representative images are shown (scale bar, 50 Wm). (() 
Thromboxane B2 (TXB2) and prostaglandin F2α (PGF2α) were found at lower levels in 
GPR55?/? tumors as assessed by mass spectrometry. (0) Interleukin ?5, ?10, and ?12 (IL?5, IL?
10, IL?12) expression was increased in GPR55?/? tumors compared to wild?type tumors, 
whereas monocyte chemoattractant protein?1 (MCP?1/CCL2) expression was decreased. (1) 
Expression levels of proliferation marker PCNA were slightly reduced in tumors of GPR55?/? 
mice whereas apoptotic markers Bax and Bcl?xL were not significantly (n.s.) altered. * 	< 
.05, ** 	< .01, *** 	< .001, n=7?12 
15	"			
,4 Leukocytes were extracted from tumors of GPR55?/? and wild?type (WT) mice 
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and analyzed by flow cytometry. (!) Viable cells were gated from an FSC/SSC plot and 
CD11b+ cells were further analyzed for their Ly6C/Ly6G expression. (/) A subpopulation of 
CD11b+ cells, i.e. Ly6C+Ly6G? cells was significantly reduced in tumors of GPR55?/? mice. (

0) Following a leukocyte gate (CD45+), cells were further gated for CD3. () Tumors of 
GPR55?/? mice showed a strong increase of CD3+ leukocytes. ((, 0) CD3+ cells were further 
analyzed for their CD4 and CD8 expression. CD4+ cells (Q1) and CD8+ cells (Q3) were more 
abundant in tumors of GPR55?/? mice than in tumors of wild?type mice. Each dot represents 
the leukocytes extracted from tumors of one mouse, and bars are the means. * 	< .05, *** 	
< .001, n=9?12 
16(		"				

. This scheme summarizes our findings of modulations that could lead to 
reduced colorectal carcinogenesis in GPR55?/? mice. Alterations in tumors of GPR55?/? mice 
compared to wild?type littermates are indicated by green arrows. Firstly, reduced numbers of 
monocytic myeloid?derived suppressor cells (MDSC) were observed which is likely a 
consequence of reduced CCL2 expression 35. Therefore, STAT3 expression in turn could be 
diminished partly by reduced CCL2?MDSC signaling 35, although other cells, e.g. neoplastic 
cells, could also play a role 44. Secondly, we observed reduced expression levels of 
transcription factor NF?κB, and of cyclooxygenase?2 (COX?2) as well as of its effector 
molecules prostaglandin F2α (PGF2α) and thromboxane B2 (TXB2). Both prostanoids have 
been shown to promote carcinogenesis 42,43. Thirdly, infiltration of both TH cells (CD4
+) and 
cytotoxic T cells (CD8+) was increased in tumors of GPR55?/? mice. Increased recruitment of 
T cells has been shown to be associated with a favorable clinical outcome in CRC 41 and 
might thus also contribute to reduced carcinogenesis in our model.  
1/
"		
	
	4 (!) In the murine colon cancer model of spontaneous tumor progression, 
CB1
?/? mice (n=7) developed more tumors and had larger tumor areas than wild?type 
littermates (WT, n=7). (/) Correspondingly, CB1
?/? mice (n=7) also had increased tumor 
numbers and total tumor areas in the model of colitis?associated CRC compared to wild?type 
littermates (n=8). Here, because of high mortality in male CB1
?/? mice after DSS application, 
only females were used. () When CB1/GPR55 double knockout (CB1
?/?GPR55?/?) mice (n=7) 
were subjected to the colitis?associated CRC model they showed a tumor burden equal to 
their wild?type littermates (n=18). Data show values obtained from individual mice, and bars 
are the means. * 	< .05, ** 	< .01, n.s. not significant 
17/	#!&		(#!		
			4 (!, /) mRNA expression levels were determined by qRT?PCR in the 
colon of healthy control mice (healthy) and in colon tissue collected from mice subjected to 
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the colitis?associated CRC model (non?tumor and tumor), reference gene: #. (!) CB1 
mRNA was found to be up?regulated in non?tumor tissue and down?regulated in tumor tissue 
compared to healthy colon tissue. (/) GPR55 mRNA, in contrast, was down?regulated in 
non?tumor tissue compared to healthy control colon whereas it was up?regulated in tumors. 
Statistical analysis for graphs ! and / was performed using one?way ANOVA and Tukey’s 
posthoc test. * 	< .05, *** 	< .001 (?1) Data of CRC patients were obtained from 
OncoTrack. (, () mRNA expression levels were obtained by RNAseq. Tumors (n=86) were 
TNM staged according to the guidelines of the Union internationale contre le cancer (UICC). 
Control samples (n=21) were obtained from tumor?adjacent non?neoplastic colon of CRC 
patients. Statistical analysis was done by one?way ANOVA followed by Tukey’s posthoc test. 
* 	< .05, *** 	< .001 () CB1 mRNA was down?regulated in tumors but increased with 
disease severity. (() In contrast, GPR55 mRNA decreased with stage. (0, 1) DNA 
methylation status was assessed in tumor samples (n=81, white bars) and in tumor?free 
control tissue (n=67, black bars). Each set of bars shows the mean + SEM degree of 
methylation in one CpG. The hg19 coordinate of each CpG is indicated by the x?axis label. 
Statistical analysis was performed with a regularized t?test that was conducted using the 
limma package in R as described in detail elsewhere27;  values were adjusted for multiple?
testing using the false?discovery method. * 	< .01, ** 	< .001, *** 	< .0001 (0) In tumor 
samples, 45 methylation was increased at CpG islands surrounding the promoter region 
whereas it was decreased in the body of the gene. (1) 5** lacks CpG islands and rather 
exhibits a global decrease in methylation in tumor samples. () GPR55 mRNA levels were 
increased in DLD?1, HCT116, SW620, and HT29 cells after treatment with 5?Aza?dC. Data 
shown are means + SEM of three independent experiments, reference gene: #53. (8) 
Stable over?expression of GPR55 led to a growth advantage of SW480 cells. Data shown are 
means + SD of six independent experiments. Statistical analysis was done by one?way 
ANOVA and Tukey’s posthoc test. * 	< .05, ** 	< .01 
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